Pharmaceutical Patents

Most powerful exclusivity for truly novel drugs.

Applies to supplements, line extensions. Much weaker than NCE exclusivity.

Highly valuable — a 6-month extension on a blockbuster drug can be worth hundreds of millions.

Runs separately from patents; applies even if no patent.

One extension per drug, applied to one patent. Most blockbuster drugs use this.

1

2

3

4

5

6

What is the Hatch-Waxman Act and how does it affect drug patents?

The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) created the modern framework for pharmaceutical patent law in the United States. It balanced two competing interests: (1) Brand-name drug company incentives: Hatch-Waxman created the patent term extension (35 U.S.C. § 156) to compensate drug companies for patent term lost during the long FDA regulatory review process. Before Hatch-Waxman, the FDA review period (often 7–12 years after filing) ate into the patent term, leaving companies with only a few years of exclusivity. The extension can add up to 5 years, subject to a cap of 14 years of remaining term after FDA approval. Hatch-Waxman also codified regulatory exclusivities (NCE exclusivity, pediatric exclusivity) that run independent of patents. (2) Generic drug market access: Hatch-Waxman created the Abbreviated New Drug Application (ANDA) process, which allows generic companies to rely on the brand drug's FDA safety and efficacy data and demonstrate only bioequivalence — without repeating full clinical trials. Hatch-Waxman also established the Paragraph IV challenge mechanism, allowing generics to challenge the validity or enforceability of listed patents before the patent expires, accelerating generic entry. The result: the US has one of the world's most complex drug patent systems, mixing traditional patent law, FDA regulatory exclusivities, Orange Book listing requirements, and specialized litigation rules — all designed to balance innovation and access.

What is the Orange Book and which patents are listed in it?

The Orange Book — formally 'Approved Drug Products with Therapeutic Equivalence Evaluations' — is an FDA publication listing all approved small-molecule drug products and the patents associated with each NDA (New Drug Application). When a brand-name company receives NDA approval, it must list in the Orange Book any patent that claims: (1) the approved drug substance (active ingredient); (2) a drug product formulation or composition; or (3) a method of using the drug (method of treatment). The brand company is required to submit Orange Book patents within 30 days of NDA approval (or patent issuance, if after approval). When a generic company files an ANDA, it must certify to each Orange Book patent: Paragraph I (no patent listed), Paragraph II (patent expired), Paragraph III (generic will wait until patent expires), or Paragraph IV (patent is invalid, unenforceable, or will not be infringed by the generic product). What is NOT listable in the Orange Book: process patents (manufacturing methods); patents that claim the compound but not in the form covered by the NDA; packaging patents. The FDA does not independently verify that listed patents qualify for Orange Book listing — the brand company certifies. Courts have found cases where improperly listed patents were challenged in antitrust actions. The Orange Book also lists regulatory exclusivities (NCE, pediatric) which are FDA-administered and not IP rights.

How does a Paragraph IV patent challenge work?

A Paragraph IV certification is a formal legal assertion by a generic drug company that a listed Orange Book patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Here is the process: (1) Generic files ANDA with Paragraph IV certification: the ANDA must include detailed basis for why each listed patent is invalid (with invalidity arguments) or not infringed (with non-infringement arguments); (2) Notice to patent owner and NDA holder: the generic filer must send a detailed notice letter within 20 days of FDA acceptance of the ANDA — the notice must provide specific factual and legal bases for the invalidity or non-infringement contentions; (3) 45-day window to file suit: the brand company has 45 days from receipt of the notice letter to file a patent infringement suit in federal district court — typically using a declaratory judgment of infringement / invalidity; (4) Automatic 30-month stay: filing suit within 45 days automatically stays FDA approval of the ANDA for 30 months (measured from date of notice) or until a court enters judgment (whichever is earlier) — this is the brand company's most powerful weapon; (5) District court litigation: typical Paragraph IV case involves claim construction, invalidity challenges (obviousness, anticipation, § 112), and non-infringement arguments; often settled; (6) 180-day first-filer exclusivity: the first generic company to file a Paragraph IV ANDA for a given drug gets 180 days of market exclusivity after first commercial marketing — creates an enormously valuable 'patent litigation lottery' incentive.

What is drug patent 'evergreening'?

Patent evergreening refers to strategies brand-name pharmaceutical companies use to extend effective market exclusivity beyond the original compound patent's expiration. Common strategies: (1) Formulation patents: after the active ingredient patent expires, list a new patent on the formulation, extended-release mechanism, tablet coating, or delivery system; (2) Metabolite patents: file patents on the active metabolite of the drug (the form the body actually uses) — relevant where the compound itself may be obvious but the metabolite was separately discovered; (3) Method-of-use patents: file additional method-of-treatment patents for new indications discovered after the original patent; (4) Pediatric exclusivity: conduct FDA-requested pediatric studies to earn 6 months of additional exclusivity added to the existing exclusivity period — the most predictable form of evergreening; (5) Polymorph patents: pharmaceutical compounds exist in different crystalline forms (polymorphs) — each may be separately patentable if the polymorph has unexpected properties. Evergreening is legal under current law, but it is the target of ongoing legislative proposals (CREATES Act, and various generic access bills). The patent dance under the BPCIA for biologics has similar dynamics. Anti-evergreening argument: multiple secondary patents extend exclusivity by years without proportional innovation, delaying generic entry and keeping drug prices high. Defense: secondary patents do represent real innovation (extended-release formulations improve patient compliance, reduce side effects); the patent system properly rewards all incremental improvements meeting the patentability standard.

How are biologic drugs protected differently from small-molecule drugs?

Biologic drugs (large-molecule drugs including monoclonal antibodies, peptides, proteins, gene therapies) are regulated under a separate framework from small-molecule drugs. The Biologics Price Competition and Innovation Act (BPCIA, 2010), part of the Affordable Care Act, created the biosimilar pathway as the biologic equivalent of Hatch-Waxman. Key differences: (1) Exclusivity: biologics receive 12 years of reference product exclusivity from first licensure (vs. 5-year NCE exclusivity for small molecules) — this is a longer baseline protection, reflecting the greater investment in biologic development and clinical trials. (2) The patent dance (42 U.S.C. § 262(l)): the BPCIA established an information exchange procedure where the biosimilar applicant shares its application with the reference product sponsor, both sides identify relevant patents, and the parties negotiate which patents to litigate before the biosimilar launch — a complex multi-step dance with specific timelines. (3) No automatic stay: unlike Hatch-Waxman's automatic 30-month stay, BPCIA has no automatic stay — the reference product sponsor must seek a preliminary injunction to delay biosimilar launch. (4) 180-day notice before launch: biosimilar applicant must give 180-day advance notice before commercial launch, allowing the reference product sponsor to seek an injunction. (5) Patent complexity: biologics are typically protected by dozens to hundreds of patents covering composition, methods of use, manufacturing, and formulation — compared to the handful of patents typical for a small-molecule drug.